These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Predictive Value of a Genomic Classifier in Indeterminate Thyroid Nodules Based on Nodule Size. Dublin JC; Papazian M; Zan E; Oweity T; Sun W; Jacobson A; Patel K; Brandler TC; Givi B JAMA Otolaryngol Head Neck Surg; 2022 Jan; 148(1):53-60. PubMed ID: 34734965 [TBL] [Abstract][Full Text] [Related]
5. Thyroid Nodules with Indeterminate FNAC According to the Italian Classification System: Prevalence, Rate of Operation, and Impact on Risk of Malignancy. An Updated Systematic Review and Meta-analysis. Trimboli P; Ferrarazzo G; Cappelli C; Piccardo A; Castellana M; Barizzi J Endocr Pathol; 2022 Dec; 33(4):457-471. PubMed ID: 36044162 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Liu R; Xing M Endocr Relat Cancer; 2014 Oct; 21(5):825-30. PubMed ID: 25121551 [TBL] [Abstract][Full Text] [Related]
7. Frequency and Significance of Censi S; Cavedon E; Bertazza L; Galuppini F; Watutantrige-Fernando S; De Lazzari P; Nacamulli D; Pennelli G; Fassina A; Iacobone M; Casal Ide E; Vianello F; Barollo S; Mian C Front Endocrinol (Lausanne); 2017; 8():273. PubMed ID: 29085338 [TBL] [Abstract][Full Text] [Related]
8. EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology and co-mutation profiles. Elsherbini N; Kim DH; Payne RJ; Hudson T; Forest VI; Hier MP; Payne AE; Pusztaszeri MP J Otolaryngol Head Neck Surg; 2022 Nov; 51(1):43. PubMed ID: 36371345 [TBL] [Abstract][Full Text] [Related]
9. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876 [TBL] [Abstract][Full Text] [Related]
11. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis. Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961 [TBL] [Abstract][Full Text] [Related]
12. The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting. Chen T; Gilfix BM; Rivera J; Sadeghi N; Richardson K; Hier MP; Forest VI; Fishman D; Caglar D; Pusztaszeri M; Mitmaker EJ; Payne RJ Thyroid; 2020 Sep; 30(9):1280-1287. PubMed ID: 32242511 [No Abstract] [Full Text] [Related]
13. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology. Macerola E; Rago T; Proietti A; Basolo F; Vitti P J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233 [TBL] [Abstract][Full Text] [Related]
14. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules. Goldner WS; Angell TE; McAdoo SL; Babiarz J; Sadow PM; Nabhan FA; Nasr C; Kloos RT Thyroid; 2019 Nov; 29(11):1594-1605. PubMed ID: 31469053 [No Abstract] [Full Text] [Related]
15. The utility of ThyroSeq Li W; Justice-Clark T; Cohen MB Cytopathology; 2021 Jul; 32(4):505-512. PubMed ID: 33914382 [TBL] [Abstract][Full Text] [Related]
16. Digital droplet PCR TERT promoter mutational screening in fine needle aspiration cytology of thyroid lesions: A highly specific technique for pre-operative identification of high-risk cases. Hysek M; Hellgren LS; Stenman A; Darai-Ramqvist E; Ljung E; Schliemann I; Condello V; Larsson C; Zedenius J; Jatta K; Juhlin CC Diagn Cytopathol; 2023 Jun; 51(6):331-340. PubMed ID: 36870048 [TBL] [Abstract][Full Text] [Related]
17. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy. Decaussin-Petrucci M; Descotes F; Depaepe L; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Lopez J Cytopathology; 2017 Dec; 28(6):482-487. PubMed ID: 29094776 [TBL] [Abstract][Full Text] [Related]
18. Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer. Kim TH; Ki CS; Hahn SY; Oh YL; Jang HW; Kim SW; Chung JH; Shin JH Endocrine; 2017 Aug; 57(2):234-240. PubMed ID: 28616852 [TBL] [Abstract][Full Text] [Related]